Seres Therapeutics, Inc. (NASDAQ:MCRB) Receives $4.00 Consensus Target Price from Brokerages

Shares of Seres Therapeutics, Inc. (NASDAQ:MCRB) have received an average recommendation of “Hold” from the five research firms that are covering the firm, Marketbeat Ratings reports. Two research analysts have rated the stock with a sell rating, one has issued a hold rating and two have assigned a buy rating to the company. The average 1 year price objective among brokers that have covered the stock in the last year is $4.00.

A number of analysts have recently issued reports on MCRB shares. StockNews.com raised shares of Seres Therapeutics from a “sell” rating to a “hold” rating in a research note on Thursday, March 6th. The Goldman Sachs Group cut their target price on shares of Seres Therapeutics from $1.00 to $0.75 and set a “sell” rating for the company in a research note on Friday.

Seres Therapeutics Trading Up 8.1 %

MCRB opened at $0.69 on Friday. Seres Therapeutics has a 1-year low of $0.54 and a 1-year high of $1.53. The company has a market capitalization of $120.10 million, a PE ratio of -3.00 and a beta of 2.19. The firm’s 50 day simple moving average is $0.79 and its two-hundred day simple moving average is $0.83.

Institutional Inflows and Outflows

A number of institutional investors have recently added to or reduced their stakes in the business. FMR LLC increased its position in Seres Therapeutics by 0.6% during the 3rd quarter. FMR LLC now owns 22,857,260 shares of the biotechnology company’s stock valued at $21,625,000 after purchasing an additional 140,096 shares during the period. Millennium Management LLC increased its position in Seres Therapeutics by 77.2% during the 4th quarter. Millennium Management LLC now owns 1,810,719 shares of the biotechnology company’s stock valued at $1,505,000 after purchasing an additional 788,762 shares during the period. Geode Capital Management LLC increased its position in Seres Therapeutics by 8.8% during the 4th quarter. Geode Capital Management LLC now owns 1,510,432 shares of the biotechnology company’s stock valued at $1,256,000 after purchasing an additional 121,793 shares during the period. Vontobel Holding Ltd. increased its position in Seres Therapeutics by 137.6% during the 4th quarter. Vontobel Holding Ltd. now owns 938,295 shares of the biotechnology company’s stock valued at $780,000 after purchasing an additional 543,469 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its position in Seres Therapeutics by 15.6% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 865,825 shares of the biotechnology company’s stock valued at $720,000 after purchasing an additional 117,107 shares during the period. Hedge funds and other institutional investors own 59.34% of the company’s stock.

About Seres Therapeutics

Seres Therapeutics, Inc, a microbiome therapeutics company, develop microbiome therapeutics to treat the modulation of the colonic microbiome. It develops a novel class of biological drugs that are designed to treat by modulating the microbiome to restore health by repairing the function of a disrupted microbiome to a non-disease state.